Why you cannot tell which peptide did it

If you are running six things at once and something feels wrong, no test and no blood panel will tell you which one is responsible. That is not a gap in your record-keeping. It is a limit of the method. Pharmacology has spent decades building a procedure for deciding whether a given compound caused a given effect, and every version of it depends on changing one variable at a time. Anyone running tirzepatide, BPC-157, TB-500 and a GHRH analogue together has already given that up.

What attribution actually requires

The formal name for the question is causality assessment. A 2008 review in the British Journal of Clinical Pharmacology, written about drug-induced liver injury but describing the general procedure, is blunt about the starting point: temporal associations as the sole criteria for a valid evaluation are not acceptable^[1]. Something happening after you started a compound is not evidence that the compound did it.

The same review lists what a real evaluation looks at: latency period, the course of liver enzymes after the compound is discontinued, risk factors, co-medication, previously published information on the compound, response to rechallenge, and exclusion of other diseases^[1]. Read that list again with a stack in mind. Co-medication is an input to the assessment, not a footnote to it. Discontinuation only tells you something if you discontinue one thing. Rechallenge only tells you something if you reintroduce one thing.

This is not a new or obscure idea. A method for estimating the probability of adverse drug reactions was published in Clinical Pharmacology and Therapeutics in 1981^[2], and the field has been refining the same logic ever since. That logic is unglamorous. Isolate, remove, observe, reintroduce, observe again.

Six compounds is not six questions

The arithmetic is worse than most people assume. Six compounds taken together do not give you six things to check. They give you six single-compound effects plus fifteen possible pairs, before you reach anything involving three compounds at once. Nobody has measured any of those fifteen pairs for a grey-market peptide combination, because nobody has run the study.

Clinical medicine already knows what happens when drug counts climb. A 2022 study of 627 people with multiple sclerosis found that 63.8% had at least one potential drug-drug interaction, with a mean of 4.6 interactions per patient, at an average of 5.3 drugs each^[3]. Those were prescribed medicines with characterised pharmacokinetics, dispensed by pharmacists, screened against interaction databases. Peptides bought as research chemicals have none of that behind them. There is no database that will screen BPC-157 against TB-500 against a GH secretagogue, because the entries do not exist.

What it takes to test two peptides properly

For a sense of the gap, look at what testing one two-peptide combination in humans actually involves. REDEFINE 1 is the phase 3 trial of cagrilintide plus semaglutide in people with overweight or obesity. It enrolled an estimated 3,400 participants across four arms: the combination, cagrilintide alone, semaglutide alone, and placebo. It started in November 2022 and is estimated to complete in October 2026^[4].

The four-arm design is the whole point. Without the single-agent arms you cannot say whether the combination did anything the components would not have done separately. That is one combination, two compounds, four years and thousands of people. A forum stack of six is asking a much harder question with a sample size of one and no control arm.

Some of the tensions are already on the label

Not every interaction here is unknown. A few are documented, and they point in directions stack-builders tend not to consider. The Mounjaro prescribing information states that tirzepatide delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications^[5]. Anything oral in the same regimen is in scope, including medicines nobody was counting as part of the stack.

There are class-level tensions too. Tesamorelin is a licensed GHRH analogue, and its US label carries a glucose warning. During clinical trials, the percentages of patients with elevated HbA1c at or above 6.5% from baseline to Week 26 were 5% and 1% in the tesamorelin and placebo groups, with an intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6) for developing diabetes relative to placebo^[6]. The label tells prescribers to evaluate glucose status before starting and to monitor IGF-1 during therapy^[6]. A growth-hormone-axis compound pushing glucose one way while an incretin drug is being used to push it the other is not a theoretical worry. The unlicensed GHRH and GH secretagogue products people actually stack carry no label at all, so the equivalent warning simply never reaches the reader.

What this does not mean

None of this says a stack is certain to harm you. The claim is narrower and more useful than that: a stack cannot produce information. If you feel better, you will not know which compound to keep. If you feel worse, you will not know which one to drop, and dropping all of them at once teaches you nothing either. Blood results that come back scattered across six markers are behaving exactly as they should, because six inputs moved.

The version of this that generates an answer is one compound at a time, held long enough to see what it does, with a clinician who knows what you are taking and can order the right follow-up. Our pages on BPC-157 and retatrutide set out what is known about each on its own, which is the honest place to start. Most of these compounds are not approved medicines in the countries we cover, and the regulatory status is a separate problem that does not go away because a combination sounds appealing. This article is not medical advice. If you are considering any of this, take it to a healthcare provider first.